Content about Gilead Sciences

May 23, 2013
More physicians 'warehousing' patients as they await new hepatitis C treatments

In anticipation of new treatments for hepatitis C, a growing number of physicians have begun intentionally delaying treatment for patients, according to a new study.

April 30, 2013
FDA delays approval of Gilead HIV drugs

The Food and Drug Administration declined to approve two drugs for HIV made by Gilead Sciences for which the company was seeking approval for use as part of treatment regimens.

April 4, 2013
FDA grants tentative approval to Aurobindo HIV drug

The Food and Drug Administration has given preliminary approval to a drug made by Aurobindo Pharma for treating HIV infection, the drug maker said.

February 19, 2013
Gilead voluntarily recalls one lot of injected AIDS-related infection drug

Drug maker Gilead Sciences has recalled a single lot of an injected drug used to treat an opportunistic infection in AIDS patients due to the presence of foreign matter, the company said.

January 15, 2013
Switching to multi-pill generic HIV treatment could diminish effectiveness, study finds

While replacing a single combination pill for HIV with generics would save the healthcare system money, it could also diminish the effectiveness of treatment, a new study suggests.

December 28, 2012
Teva delays sales of Gilead generics pending court ruling

Teva Pharmaceuticals USA will delay the sales of generic versions of two Gilead Sciences HIV drugs until June 2013, the company stated.

August 3, 2012
Mylan, Gilead sign HIV/AIDS drug deal

Mylan and Gilead Sciences have made an agreement under which Mylan will have rights to produce and market generic versions of Gilead drugs for HIV and AIDS in developing countries.

July 16, 2012
Gilead's Truvada approved for PrEP

The Food and Drug Administration has approved a drug used to treat HIV for reducing the risk of HIV infection, the agency said Monday.

June 29, 2012
Gilead seeks approval for HIV drug-boosting agent

Drug maker Gilead Sciences has submitted a regulatory approval application to the Food and Drug Administration for a drug designed to increase the blood levels of certain drugs for HIV.

May 14, 2012
FDA panel recommends approval for experimental Gilead HIV drug

A Food and Drug Administration expert panel has recommended approval of a drug made by Gilead Sciences for treating HIV, the drug maker said Friday.

May 11, 2012
FDA advisory committee recommends PrEP approval for Truvada

An expert panel at the Food and Drug Administration has recommended that the agency approve a drug made by Gilead Sciences for lowering the risk of infection by the virus that causes AIDS.

May 9, 2012
Reports: FDA may be close to approving drug for HIV prevention

The Food and Drug Administration may be close to approving a drug for preventing HIV infection, according to published reports.

February 14, 2012
FDA grants priority review to Gilead's Truvada for HIV prevention

The Food and Drug Administration is giving priority review to a drug made by Gilead Sciences that the company is investigating for the prevention of HIV.

January 19, 2012
Gilead receives FDA approval for lower-dose HIV drug in children

The Food and Drug Administration has approved a lower-dose formulation of a drug made by Gilead Sciences for treating HIV in children, the company said.

January 18, 2012
Gilead completes acquisition of Pharmasset

Drug maker Gilead Sciences has completed its $11.2 billion acquisition of Pharmasset, Gilead said.

January 3, 2012
FDA accepts application for Gilead HIV drug

The Food and Drug Administration has accepted a regulatory approval application from Gilead Sciences for a drug to treat HIV, the company said.

November 21, 2011
Gilead Sciences acquires Pharmasset for $11 billion

Drug maker Gilead Sciences will acquire Pharmasset for $11 billion, or $137 per share, Gilead said Monday.

October 27, 2011
Bristol-Myers Squibb, Gilead Sciences to develop, commercialize HIV combo treatment

Drug makers Bristol-Myers Squibb and Gilead Sciences announced an agreement to develop and commercialize a fixed-dose combination treatment for patients with HIV.

October 6, 2011
Gilead, Boehringer Ingelheim ink license agreement

Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.

August 11, 2011
FDA approves single-pill HIV drug

The Food and Drug Administration has approved a new single-pill treatment for HIV made by Gilead Sciences and Johnson & Johnson, Gilead said.

July 19, 2011
Matrix expands licensing agreement with Gilead for HIV/AIDS therapies

Mylan subsidiary Matrix Labs has expanded its licensing agreement with Gilead Sciences.

July 19, 2011
Ranbaxy to produce, market antiretrovirals under licensing agreement with Gilead

Ranbaxy will produce and market three HIV/AIDS drugs that currently are in late-stage clinical development by Gilead under a new licensing agreement between the drug makers.

July 13, 2011
Studies find HIV drug treatments may reduce infection risk among heterosexual couples

Taking drugs for treating HIV might reduce the risk of infection among heterosexual couples, according to two new studies conducted in Africa.

June 30, 2011
Physicians urge FDA not to approve Truvada

A group of physicians is urging the Food and Drug Administration not to approve a drug made by Gilead Sciences for the prevention of HIV infection.

June 28, 2011
Gilead, Tibotec to develop HIV drug

A subsidiary of Johnson & Johnson and Gilead Sciences will collaborate to develop a combination drug for HIV, the two companies said Tuesday.

© 2013 Drug Store News. All Rights Reserved.